PFE: A Frozen Dividend and a 15-Year Streak on the Clock

Seven quarters at exactly $0.43

Pfizer has held its quarterly dividend at exactly $0.43 for seven straight quarters — all of 2025 through the Q3 2026 dividend payable September 1 (the 351st consecutive quarterly dividend, and the seventh at $0.43). It hasn't been cut. It also hasn't been raised.

That matters because a frozen payout is its own state, sitting between a healthy grower and a cut. And the calendar makes it concrete. Pfizer sets its annual dividend rate at its December declaration — the one that fixes the following year's first-quarter payment. In December 2025 the board held flat at $0.43 (the 349th consecutive quarterly dividend), which means all four 2026 quarters pay $0.43 and calendar-2026 dividends total $1.72 — the same as 2025. On the annual-rate basis most streak trackers use, 2026's growth has effectively already stalled. What's genuinely live is the December 2026 declaration: it sets the first-quarter 2027 payment, and it decides whether Pfizer's roughly 15-year growth streak extends or breaks outright.

So an income investor holding a ~6% yielder is watching a streak that has already quietly stopped growing this year, with the real make-or-break call still ahead in December. This piece lays out what the numbers say on both sides, and how to read the freeze — not to predict the declaration, but to understand what each outcome would signal. It is for educational purposes only and is not investment advice.

Performance and yield figures are historical and may change. Total return includes price movement and distributions where available. Past performance does not guarantee future results. Yield is not the same as total return.

What the one-year chart shows

The total-return chart above complicates any clean "washed-out bargain" narrative — and it cuts against Pfizer. Over the trailing year GSK has returned roughly 37% and AbbVie roughly 31%, while Pfizer has returned about 19% — the weakest of the three. At $28.07 the stock sits near the middle-to-upper end of its $23.58–$28.75 52-week range, not pinned at the lows.

Here's the uncomfortable part for the bull case: the "reset cousin," GSK — the one that actually reset its dividend — has been both the best one-year performer here and, as the coverage table below shows, the name with the strongest dividend coverage. That's the tension worth sitting with, not walking past. Against the peers the lines diverge sharply: AbbVie at $264.96 trades essentially at the top of its $190.75–$267.47 range; GSK's ADR at $52.41 sits mid-range within $38.63–$61.70. This isn't three healthcare names sinking together; it's three very different dividend stories, which is exactly why the comparison is useful rather than a wash.

How Pfizer makes money

Pfizer is a large-cap pharmaceutical manufacturer: it develops, patents, and sells branded medicines and vaccines, then defends those franchises against patent expirations with new products and acquisitions. The economics are high-margin — FY2025 gross margin was about 74% — but they live and die by the pipeline replacing what goes off-patent.

The recent financials carry a COVID hangover that distorts any five-year glance. Revenue was $100.33B in FY2022 at the peak of pandemic-related sales, then reset hard as that business faded:

The honest read: FY2022 is the anomaly, not the baseline. Revenue has settled into the low-$60B range with gross margins back near 74%. The five-year price decline that shows up on long charts is largely the market re-rating away from peak-COVID earnings — a real move, but not the same thing as a business in structural decline.

The dividend, and the coverage that actually matters

Pfizer's trailing yield is 6.13% — the highest of the three names here by a wide margin. The $0.43 quarterly payout annualizes to $1.72 per share.